Literature DB >> 6936079

Fatal hepatic necrosis after high-dose chemotherapy following haloalkane anesthesia.

R J Spiegel, P A Pizzo, J C Fantone, H J Zimmerman.   

Abstract

We describe two patients who died with rapidly progressive hepatic necrosis following intensive chemotherapy and haloalkane anesthesia. Intensive multiple-drug chemotherapy has been associated with severe systemic toxic effects, but fulminant hepatic necrosis has not been recognized as a frequent complication. Furthermore, overt hepatic injury following the currently used halogenated anesthetic agents alone is rare without prior exposure and generally is considered to be idiosyncratic, ie, dependent upon unusual patient vulnerability. The unanticipated hepatic failure in these patients is reported to alert clinicians to this potential complication of intensive cancer chemotherapy and the possible additive adverse effect of haloalkane anesthesia.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6936079

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

1.  Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane.

Authors:  S Rosenow; K L Kooistra; G Powis; R A Van Dyke
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Inhibition of 7-hydroxymethotrexate formation by amsacrine.

Authors:  R M Bremnes; E Smeland; N P Willassen; E Wist; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Mechanisms of hepatotoxicity caused by dacarbazine in rats.

Authors:  R Paschke; M Heine; S Braun; K H Usadel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission.

Authors:  Satoshi Ohno; Yoshiteru Sumiyoshi; Katsuyoshi Hashine; Akitomi Shirato; Satoru Kyo; Masaki Inoue
Journal:  Evid Based Complement Alternat Med       Date:  2011-04-18       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.